<DOC>
	<DOCNO>NCT00246805</DOCNO>
	<brief_summary>The purpose study monitor heart rate regularization patient permanent atrial fibrillation standard indication single chamber rate adaptive pacing VVI ( R ) .</brief_summary>
	<brief_title>Heart Rate Regularization Patients With Permanent Atrial Fibrillation Post Marketing Study</brief_title>
	<detailed_description>The RARE PEARL multicenter prospective , randomize , double-blinded , crossover study . Prior enter study patient inform give write consent . Besides he/she meet selection criterion . The Investigator check selection criterion satisfy . Then patient undergoes pacemaker implantation , receive pacemaker model C20 SSIR T20 SSIR ( later ) . The ventricular lead must bipolar independently manufacturer . After pacemaker implantation , 45 day Stabilization Period necessary stabilize lead drug therapy . At end stabilization period patient randomize VRS algorithm switch either ON OFF . The 1° Study Phase end 2 month . Then cross-over take place : VRS algorithm switch respectively OFF ON 2° Study Phase start . Also 2° Study Phase end 2 month . The randomization centralize : randomization list generate manage sponsor . Because patient undergo QoL questionnaire crossover phase , blind status VRS setting . Similarly , also co-investigators administer QoL questionnaire blind status VRS setting . Only principal investigator know VRS algorithm ON OFF . The principal investigator instruct inform patient co-investigators administer QoL questionnaire set end study . The co-investigator ( ) responsible QoL questionnaire perform patient follow-up 1° 2° Study Phase , otherwise patient automatically exclude study . After cross-over period ( 2 + 2 month ) Free Therapy Phase ( 3° Phase ) start . Device setting drug therapy leave physician 's discretion . One year implantation final follow-up schedule . The study end pacemaker program accord physician 's discretion .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Patient sign informed consent form Patient permanent atrial fibrillation , standard indication VVI ( R ) pacing , least 1 episode rate irregularity last month New York Heart Association ( NYHA ) Class I , II , III Patient able comply followup time comply protocol &gt; 18 year age Paroxysmal atrial fibrillation NYHA Class IV Left ventricular ejection fraction ( LVEF ) &lt; 35 Patients unstable angina Patients experience acute myocardial infarction receive coronary artery revascularization ( CABG ) , coronary angioplasty ( PTCA ) within 3 month prior enrolment Patient candidate cardiac surgery , coronary angioplasty ( PTCA ) Patients experience cardiovascular accident ( CVA ) transient ischemic attack ( TIA ) permanent disability Life expectancy &lt; 12 month due medical condition Pregnancy The patient enrol concurrent ( drug and/or device ) study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Permanent atrial fibrillation</keyword>
	<keyword>VVI ( R ) pacing</keyword>
	<keyword>rate regularization</keyword>
</DOC>